Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Leigh Perreault to Diabetes Mellitus, Type 2

This is a "connection" page, showing publications Leigh Perreault has written about Diabetes Mellitus, Type 2.

 
Connection Strength
  
 
 
5.025
  
  1. Perreault L, Bergman BC. Out of stock: A brief clinical reference for rough equivalency of glucagon-like peptide-1 (GLP-1) ? glucose-dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes. J Diabetes. 2024 Jun; 16(6):e13505.
    View in: PubMed
    Score: 0.317
  2. Ritchie ND, Sauder KA, Perreault L. Glycemic Improvement and Health Equity in the National Diabetes Prevention Program. Diabetes Care. 2023 06 01; 46(6):e128-e129.
    View in: PubMed
    Score: 0.307
  3. Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, Machineni S, Varbo A, Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care. 2022 10 01; 45(10):2396-2405.
    View in: PubMed
    Score: 0.293
  4. Ritchie ND, Sauder KA, Kaufmann PG, Perreault L. Patient-Centered Goal-Setting in the National Diabetes Prevention Program: A Pilot Study. Diabetes Care. 2021 11; 44(11):2464-2469.
    View in: PubMed
    Score: 0.271
  5. Perreault L, Skyler JS, Rosenstock J. Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nat Rev Endocrinol. 2021 06; 17(6):364-377.
    View in: PubMed
    Score: 0.265
  6. Perreault L, Vincent L, Neumiller JJ, Santos-Cavaiola T. Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions. J Am Board Fam Med. 2019 May-Jun; 32(3):431-447.
    View in: PubMed
    Score: 0.231
  7. Perreault L, Boardman MK, Pak J. The Association Between Type 2 Diabetes and Cardiovascular Disease: The "For Your SweetHeart?" Survey. Adv Ther. 2019 03; 36(3):746-755.
    View in: PubMed
    Score: 0.228
  8. Perreault L, Rodbard H, Valentine V, Johnson E. Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. Adv Ther. 2019 02; 36(2):265-277.
    View in: PubMed
    Score: 0.226
  9. Perreault L, Pan Q, Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Mather KJ, Knowler WC. Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabet Med. 2017 12; 34(12):1747-1755.
    View in: PubMed
    Score: 0.207
  10. Perreault L. EMPA-REG OUTCOME: The Endocrinologist's Point of View. Am J Med. 2017 Jun; 130(6S):S51-S56.
    View in: PubMed
    Score: 0.202
  11. Perreault L. EMPA-REG OUTCOME: The Endocrinologist's Point of View. Am J Cardiol. 2017 07 01; 120(1S):S48-S52.
    View in: PubMed
    Score: 0.202
  12. Perreault L, Temprosa M, Mather KJ, Horton E, Kitabchi A, Larkin M, Montez MG, Thayer D, Orchard TJ, Hamman RF, Goldberg RB. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care. 2014 Sep; 37(9):2622-31.
    View in: PubMed
    Score: 0.165
  13. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012 Jun 16; 379(9833):2243-51.
    View in: PubMed
    Score: 0.143
  14. Bergman BC, Hunerdosse DM, Kerege A, Playdon MC, Perreault L. Localisation and composition of skeletal muscle diacylglycerol predicts insulin resistance in humans. Diabetologia. 2012 Apr; 55(4):1140-50.
    View in: PubMed
    Score: 0.139
  15. Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care. 2009 Sep; 32(9):1583-8.
    View in: PubMed
    Score: 0.117
  16. Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025 Mar 06; 392(10):958-971.
    View in: PubMed
    Score: 0.085
  17. Zemski Berry KA, Garfield A, Jambal P, Zarini S, Perreault L, Bergman BC. Oxidised phosphatidylcholine induces sarcolemmal ceramide accumulation and insulin resistance in skeletal muscle. Diabetologia. 2024 Dec; 67(12):2819-2832.
    View in: PubMed
    Score: 0.084
  18. McKenna CF, Stierwalt HD, Zemski Berry KA, Ehrlicher SE, Robinson MM, Zarini S, Kahn DE, Snell-Bergeon JK, Perreault L, Bergman BC, Newsom SA. Intramuscular diacylglycerol accumulates with acute hyperinsulinemia in insulin-resistant phenotypes. Am J Physiol Endocrinol Metab. 2024 Aug 01; 327(2):E183-E193.
    View in: PubMed
    Score: 0.082
  19. Zarini S, Zemski Berry KA, Kahn DE, Garfield A, Perreault L, Kerege A, Bergman BC. Deoxysphingolipids: Atypical Skeletal Muscle Lipids Related to Insulin Resistance in Humans That Decrease Insulin Sensitivity In?Vitro. Diabetes. 2023 07 01; 72(7):884-897.
    View in: PubMed
    Score: 0.077
  20. Lutter D, Sachs S, Walter M, Kerege A, Perreault L, Kahn DE, Wolide AD, Kleinert M, Bergman BC, Hofmann SM. Skeletal muscle and intermuscular adipose tissue gene expression profiling identifies new biomarkers with prognostic significance for insulin resistance progression and intervention response. Diabetologia. 2023 05; 66(5):873-883.
    View in: PubMed
    Score: 0.075
  21. Zarini S, Brozinick JT, Zemski Berry KA, Garfield A, Perreault L, Kerege A, Bui HH, Sanders P, Siddall P, Kuo MS, Bergman BC. Serum dihydroceramides correlate with insulin sensitivity in humans and decrease insulin sensitivity in?vitro. J Lipid Res. 2022 10; 63(10):100270.
    View in: PubMed
    Score: 0.073
  22. Goldberg RB, Tripputi MT, Boyko EJ, Budoff M, Chen ZZ, Clark JM, Dabelea DM, Edelstein SL, Gerszten RE, Horton E, Mather KJ, Perreault L, Temprosa M, Wallia A, Watson K, Irfan Z. Hepatic Fat in Participants With and Without Incident Diabetes in the Diabetes Prevention Program Outcome Study. J Clin Endocrinol Metab. 2021 10 21; 106(11):e4746-e4765.
    View in: PubMed
    Score: 0.069
  23. Aroda VR, Christophi CA, Edelstein SL, Perreault L, Kim C, Golden SH, Horton E, Mather KJ. Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program. BMJ Open Diabetes Res Care. 2020 12; 8(2).
    View in: PubMed
    Score: 0.064
  24. Tuttle KR, Brosius FC, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJL, Manley T, McGuire DK, Molitch ME, Mottl AK, Perreault L, Rosas SE, Rossing P, Sola L, Vallon V, Wanner C, Perkovic V. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Diabetes. 2021 01; 70(1):1-16.
    View in: PubMed
    Score: 0.064
  25. Tuttle KR, Brosius FC, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJL, Manley T, McGuire DK, Molitch ME, Mottl AK, Perreault L, Rosas SE, Rossing P, Sola L, Vallon V, Wanner C, Perkovic V. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2021 01; 77(1):94-109.
    View in: PubMed
    Score: 0.064
  26. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, Blonde L, Bush MA, DeFronzo RA, Garber JR, Garvey WT, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Perreault L, Rosenblit PD, Samson S, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020 01; 26(1):107-139.
    View in: PubMed
    Score: 0.060
  27. Harman NL, Wilding JPH, Curry D, Harris J, Logue J, Pemberton RJ, Perreault L, Thompson G, Tunis S, Williamson PR. Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes. BMJ Open Diabetes Res Care. 2019; 7(1):e000700.
    View in: PubMed
    Score: 0.060
  28. Chen ZZ, Liu J, Morningstar J, Heckman-Stoddard BM, Lee CG, Dagogo-Jack S, Ferguson JF, Hamman RF, Knowler WC, Mather KJ, Perreault L, Florez JC, Wang TJ, Clish C, Temprosa M, Gerszten RE. Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program. Diabetes. 2019 12; 68(12):2337-2349.
    View in: PubMed
    Score: 0.059
  29. Perreault L, Pan Q, Schroeder EB, Kalyani RR, Bray GA, Dagogo-Jack S, White NH, Goldberg RB, Kahn SE, Knowler WC, Mathioudakis N, Dabelea D. Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes Care. 2019 09; 42(9):1809-1815.
    View in: PubMed
    Score: 0.059
  30. Perreault L. GOALS FOR MEDICAL TREATMENT IN OBESITY AND PREDIABETES: IMPROVING OUTCOMES FOR BOTH. Endocr Pract. 2018 Dec; 24(12):1093-1098.
    View in: PubMed
    Score: 0.056
  31. Harman NL, Wilding J, Curry D, Harris J, Logue J, Pemberton RJ, Perreault L, Thompson G, Tunis S, Williamson PR. Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set. Trials. 2018 Aug 07; 19(1):427.
    View in: PubMed
    Score: 0.055
  32. Perreault L, Newsom SA, Strauss A, Kerege A, Kahn DE, Harrison KA, Snell-Bergeon JK, Nemkov T, D'Alessandro A, Jackman MR, MacLean PS, Bergman BC. Intracellular localization of diacylglycerols and sphingolipids influences insulin sensitivity and mitochondrial function in human skeletal muscle. JCI Insight. 2018 02 08; 3(3).
    View in: PubMed
    Score: 0.053
  33. Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, Nathan DM. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia. 2017 09; 60(9):1601-1611.
    View in: PubMed
    Score: 0.051
  34. Goldberg RB, Temprosa M, Mele L, Orchard T, Mather K, Bray G, Horton E, Kitabchi A, Krakoff J, Marcovina S, Perreault L, White N. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. Metabolism. 2016 May; 65(5):764-775.
    View in: PubMed
    Score: 0.046
  35. Perreault L, Starling AP, Glueck D, Brozinick JT, Sanders P, Siddall P, Kuo MS, Dabelea D, Bergman BC. Biomarkers of Ectopic Fat Deposition: The Next Frontier in Serum Lipidomics. J Clin Endocrinol Metab. 2016 Jan; 101(1):176-82.
    View in: PubMed
    Score: 0.045
  36. Hivert MF, Christophi CA, Franks PW, Jablonski KA, Ehrmann DA, Kahn SE, Horton ES, Pollin TI, Mather KJ, Perreault L, Barrett-Connor E, Knowler WC, Florez JC. Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016 Feb; 65(2):520-6.
    View in: PubMed
    Score: 0.045
  37. Bergman BC, Brozinick JT, Strauss A, Bacon S, Kerege A, Bui HH, Sanders P, Siddall P, Kuo MS, Perreault L. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. Am J Physiol Endocrinol Metab. 2015 Aug 15; 309(4):E398-408.
    View in: PubMed
    Score: 0.044
  38. Kim C, Christophi CA, Goldberg RB, Perreault L, Dabelea D, Marcovina SM, Pi-Sunyer X, Barrett-Connor E. Adiponectin, C-reactive protein, fibrinogen and tissue plasminogen activator antigen levels among glucose-intolerant women with and without histories of gestational diabetes. Diabet Med. 2016 Jan; 33(1):32-8.
    View in: PubMed
    Score: 0.044
  39. Perreault L, F?rch K, Kerege AA, Bacon SD, Bergman BC. Hepatic glucose sensing is impaired, but can be normalized, in people with impaired fasting glucose. J Clin Endocrinol Metab. 2014 Jul; 99(7):E1154-62.
    View in: PubMed
    Score: 0.041
  40. Perreault L, F?rch K. Approaching pre-diabetes. J Diabetes Complications. 2014 Mar-Apr; 28(2):226-33.
    View in: PubMed
    Score: 0.039
  41. F?rch K, Witte DR, Tab?k AG, Perreault L, Herder C, Brunner EJ, Kivim?ki M, Vistisen D. Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. Lancet Diabetes Endocrinol. 2013 Sep; 1(1):43-51.
    View in: PubMed
    Score: 0.038
  42. Kim C, Edelstein SL, Crandall JP, Dabelea D, Kitabchi AE, Hamman RF, Montez MG, Perreault L, Foulkes MA, Barrett-Connor E. Menopause and risk of diabetes in the Diabetes Prevention Program. Menopause. 2011 Aug; 18(8):857-68.
    View in: PubMed
    Score: 0.034
  43. Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, Hamman RF, Kahn SE, Haffner S, Meigs JB, Altshuler D, Knowler WC, Florez JC. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes. 2011 Apr; 60(4):1340-8.
    View in: PubMed
    Score: 0.033
  44. Crandall JP, Polsky S, Howard AA, Perreault L, Bray GA, Barrett-Connor E, Brown-Friday J, Whittington T, Foo S, Ma Y, Edelstein SL. Alcohol consumption and diabetes risk in the Diabetes Prevention Program. Am J Clin Nutr. 2009 Sep; 90(3):595-601.
    View in: PubMed
    Score: 0.029
  45. Davies M, F?rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2?4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 03 13; 397(10278):971-984.
    View in: PubMed
    Score: 0.016
  46. Kahn D, Perreault L, Macias E, Zarini S, Newsom SA, Strauss A, Kerege A, Harrison K, Snell-Bergeon J, Bergman BC. Subcellular localisation and composition of intramuscular triacylglycerol influence insulin sensitivity in humans. Diabetologia. 2021 01; 64(1):168-180.
    View in: PubMed
    Score: 0.016
  47. Sachs S, Zarini S, Kahn DE, Harrison KA, Perreault L, Phang T, Newsom SA, Strauss A, Kerege A, Schoen JA, Bessesen DH, Schwarzmayr T, Graf E, Lutter D, Krumsiek J, Hofmann SM, Bergman BC. Intermuscular adipose tissue directly modulates skeletal muscle insulin sensitivity in humans. Am J Physiol Endocrinol Metab. 2019 05 01; 316(5):E866-E879.
    View in: PubMed
    Score: 0.014
  48. Herman WH, Pan Q, Edelstein SL, Mather KJ, Perreault L, Barrett-Connor E, Dabelea DM, Horton E, Kahn SE, Knowler WC, Lorenzo C, Pi-Sunyer X, Venditti E, Ye W. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. Diabetes Care. 2017 12; 40(12):1668-1677.
    View in: PubMed
    Score: 0.013
  49. Bergman BC, Perreault L, Strauss A, Bacon S, Kerege A, Harrison K, Brozinick JT, Hunerdosse DM, Playdon MC, Holmes W, Bui HH, Sanders P, Siddall P, Wei T, Thomas MK, Kuo MS, Eckel RH. Intramuscular triglyceride synthesis: importance in muscle lipid partitioning in humans. Am J Physiol Endocrinol Metab. 2018 02 01; 314(2):E152-E164.
    View in: PubMed
    Score: 0.013
  50. Newsom SA, Brozinick JT, Kiseljak-Vassiliades K, Strauss AN, Bacon SD, Kerege AA, Bui HH, Sanders P, Siddall P, Wei T, Thomas M, Kuo MS, Nemkov T, D'Alessandro A, Hansen KC, Perreault L, Bergman BC. Skeletal muscle phosphatidylcholine and phosphatidylethanolamine are related to insulin sensitivity and respond to acute exercise in humans. J Appl Physiol (1985). 2016 Jun 01; 120(11):1355-63.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)